Latest Us Market News

Dimerix has inked an exclusive US licensing agreement with Amicus Therapeutics for DMX-200, a promising Phase 3 treatment for FSGS, unlocking $30 million upfront and up to $560 million in milestones.

Australian Strategic Materials (ASM) outlines progress on its Korean Metals Plant ramp-up, strategic plans for a US metals facility, and conditional funding support for the Dubbo Project, reinforcing its mine-to-metals supply chain ambitions.

Burgundy Diamond Mines reported a challenging Q1-2025 with lower ore mined and revenue, yet continues to progress development at Point Lake and Misery mines while strengthening its financial position.

Ovanti Limited has taken decisive steps to accelerate its US Buy Now Pay Later (BNPL) market entry, appointing an interim CEO and securing a pivotal 20-year licensing agreement with BNPLPay Protocol that offers low-cost funding and a significant revenue share.

Clime Investment Management has been appointed lead manager for a significant US public offer fund by Sphinx Investments, with initial allocations of $183 million AUD pending SEC approval. The move marks a strategic expansion into the US market, complemented by new wholesale offerings and a partnership with a Dallas-based equities manager.

QX Resources reported steady progress on its Queensland gold and US lithium brine projects while managing modest cash reserves and exploration expenditure in the March 2025 quarter.

TZ Limited reported a challenging Q3 FY2025 with a $1.03 million net cash outflow amid US tariff disruptions but strengthened its SaaS base through the Keyvision acquisition, positioning for a rebound and growth in FY2026.

FBR Limited wraps up its US Demonstration Program, secures $6.3 million in capital, and appoints Mark Pivac as CEO amid a 70% cost reduction drive. Strategic collaborations with Samsung Heavy Industries and Liebherr signal broader automation ambitions.

Stakk Limited reports a staggering 2,533% quarter-on-quarter increase in annual recurring revenue to $472k, fueled by its acquisition of US-based Radical DBX and rapid expansion in Embedded Finance across Australia and the US.

Hydralyte North America reported a 16% rise in Q1 FY25 net sales and improved gross margins, supported by a strategic capital raise and upcoming product launches targeting brain and gut health.

Inventis Limited reported solid Q3 cash generation and strong technology sales growth, while actively pursuing international expansion and a $2.5 million USD capital raise for its US Hazavoid entity.

Dimerix Limited advances its Phase 3 kidney disease trial with FDA acceptance of proteinuria as a primary endpoint and clinches a lucrative licensing agreement in Japan worth up to AU$107 million plus royalties.